RxDoctor Payments Data

Mary Piergallini, MD

Family Medicine · Lock Haven, PANPI 1326018607

Payments from drug & device makers

$326in general payments, 2019–2025

Across 24 payments — averaging $13.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$43
  • Sanofi-aventis U.S. LLC$42
  • Boehringer Ingelheim$41
  • GSK$40
  • Novartis$31
  • Amgen$30
  • plus $99 from 7 others

What the payments were for

  • Food & beverage$326100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$326 in reported general payments places this provider in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$67,380
Medicare patients
119
Services billed
956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$99,667
OzempicSemaglutide55$64,303
Tresiba Flextouch U-200Insulin Degludec33$51,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$42,936
RybelsusSemaglutide28$40,637
XareltoRivaroxaban47$34,445
JardianceEmpagliflozin38$31,613
JanuviaSitagliptin Phosphate19$29,893
TrulicityDulaglutide11$18,087
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$16,639
LinzessLinaclotide16$14,178
Breo ElliptaFluticasone/Vilanterol12$10,950
MyrbetriqMirabegron16$10,398
Janumet XrSitagliptin Phos/Metformin Hcl11$8,666
Incruse ElliptaUmeclidinium Bromide11$6,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$30$104,93983 claims
PfizerEliquis$12$99,667108 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$40$76,901106 claims
Boehringer IngelheimJardiance, Tradjenta$41$36,38349 claims
Johnson & JohnsonXarelto$11$34,44547 claims
Lilly USA, LLCTrulicity$43$18,08711 claims
Astellas Pharma US IncMyrbetriq$17$10,39816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Lock Haven

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →